PSMA ligands in prostate cancer – Probe optimization and theranostic applications
- 1 November 2017
- journal article
- research article
- Published by Elsevier BV in Methods
- Vol. 130, 42-50
- https://doi.org/10.1016/j.ymeth.2017.06.026
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology, 2013
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate‐Specific Membrane AntigenAngewandte Chemie-International Edition, 2011
- Spacer Effects on in vivo Properties of DOTA-Conjugated Dimeric [Tyr3]Octreotate Peptides Synthesized by a “CuI-Click” and “Sulfo-Click” Ligation MethodChemBioChem, 2011
- A low molecular weight PSMA-based fluorescent imaging agent for cancerBiochemical and Biophysical Research Communications, 2009
- Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate CancerJournal of Medicinal Chemistry, 2008
- Pseudoirreversible Inhibition of Prostate-Specific Membrane Antigen by Phosphoramidate PeptidomimeticsBiochemistry, 2008
- Therapeutic Radionuclides: Biophysical and Radiobiologic PrinciplesSeminars in Nuclear Medicine, 2008
- Progress in the discovery and development of glutamate carboxypeptidase II inhibitorsDrug Discovery Today, 2007
- Synthesis and Biological Evaluation of Thiol-Based Inhibitors of Glutamate Carboxypeptidase II: Discovery of an Orally Active GCP II InhibitorJournal of Medicinal Chemistry, 2003